Market Research Consumer Goods Market Research Consumer Goods & Retailing Market Research Retailing Market Research Drug Stores Market Research

Bleeding Disorders Market By Disease Type (Hemophilia A, Hemophilia B, Von Willebrand Disease, Others), By Treatment Type (Factor Replacement Therapy, Drug Therapy), By Distribution Channel (Hospital Pharmacies, Drug stores and retail pharmacies, Online p

Best Price Guarantee Length Publisher Published Date SKU
from $3,840 458 Pages Allied Market Research May, 2023 ALMR18132583
Best Price Guarantee
Price from $3,840
Length 458 Pages
Publisher Allied Market Research
Published Date May, 2023
SKU ALMR18132583

Bleeding Disorders Market By Disease Type (Hemophilia A, Hemophilia B, Von Willebrand Disease, Others), By Treatment Type (Factor Replacement Therapy, Drug Therapy), By Distribution Channel (Hospital Pharmacies, Drug stores and retail pharmacies, Online pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032


The bleeding disorders market was valued at $13,789.66 million in 2022 and is estimated to reach $25,974.82 million by 2032, exhibiting a CAGR of 6.6% from 2023 to 2032.

Bleeding disorders are a group of conditions characterized by abnormal bleeding due to the deficiency or dysfunction of certain clotting factors in the blood. Normally, when a person experiences an injury or cut, the body forms a clot to stop bleeding. However, in a person with a bleeding disorder, this process is impaired or absent, which may lead to abnormal or excessive bleeding. Hemophilia is the most well-known and common bleeding disorder, which affects mostly males and may result in serious and life-threatening bleeding episodes. Von Willebrand disease is another common bleeding disorder that affects both males and females and may lead to prolonged bleeding after injury or surgery.

Major factors that drive the growth of the bleeding disorders market include rapid advancements in treatment of bleeding disorders; increase in number of patients suffering from hemophilia A, hemophilia B, and other bleeding disorders. For instance, according to the Centers for Disease Control and Prevention (CDC) 2022, 33,000 males in the U.S. live with the bleeding disorder.

Furthermore, favorable government initiatives for hemophilia management, increase in number of awareness programs regarding bleeding disorder treatment and rise in number of clinical trials for the development of antihemophilic drugs boost the growth of bleeding disorders market. In addition, the increase in target population, increase in diagnosis rate, and surge in the use of prophylactic treatment for hemophilia propel the market growth. 

However, the high cost of hemophilia treatment, and serious adverse effects associated with plasma derived products are expected to restrict the growth of bleeding disorders market. On the contrary, surge in healthcare expenditure, and unmet medical demands to get better treatment options for hemophilia in developing countries are expected to create immense opportunities for the expansion of the global market in the future. 

The bleeding disorders market is segmented on the basis of disease type, treatment type, distribution channel and region. On the basis of disease type, the market is classified into hemophilia A, hemophilia B, Von Willebrand disease and others. On the basis of treatment type, the market is classified into factor replacement therapy, and drug therapy (desmopressin, antifibrinolytics, fibrin sealant). The factor replacement therapy segment is further bifurcated into plasma-derived coagulation factor concentrates, and recombinant coagulation factor concentrates. On the basis of distribution channel, the bleeding disorders market is segmented into hospital pharmacies, drugs stores and retail pharmacies, and online pharmacies. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA). 

Major players profiled in the report are Bayer AG, CSL Ltd. (CSL Behring), F. Hoffmann-La Roche AG, Grifols, S.A., Medexus Pharma, Inc., Novo Nordisk A/S, Octapharma AG, Pfizer Inc., SANOFI CORPORATION, and Takeda Pharmaceutical Company Limited. The major players in the market have adopted investment, partnership and product approvals as key developmental strategies to improve the product portfolio of the bleeding disorders market.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the bleeding disorders market analysis from 2022 to 2032 to identify the prevailing bleeding disorders market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the bleeding disorders market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global bleeding disorders market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Disease Type

Hemophilia A
Hemophilia B
Von Willebrand Disease
Others

By Treatment Type

Factor Replacement Therapy
Type
Recombinant coagulation factor concentrates
Plasma derived coagulation factor concentrates
Drug Therapy

By Distribution Channel

Hospital Pharmacies
Drug stores and retail pharmacies
Online pharmacies

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Medexus Pharma, Inc.
Bayer AG
Novo Nordisk A/S
Grifols, S.A.
Octapharma AG
Takeda Pharmaceutical Company Limited
CSL Limited
Pfizer Inc.
Sanofi
F. Hoffmann-La Roche Ltd.

Please Note: It will take 7-10 business days to complete the report upon order confirmation.


CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of hemophilia
3.4.1.2. Technological advancements in treatment of hemophilia
3.4.1.3. Favorable government initiatives for hemophilia management
3.4.2. Restraints
3.4.2.1. High cost of bleeding disorders treatments
3.4.3. Opportunities
3.4.3.1. Rise in awareness about bleeding disorders in developing countries
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: BLEEDING DISORDERS MARKET, BY DISEASE TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Hemophilia A
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Hemophilia B
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Von Willebrand Disease
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Others
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
CHAPTER 5: BLEEDING DISORDERS MARKET, BY TREATMENT TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Factor Replacement Therapy
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.2.4. Factor Replacement Therapy Bleeding Disorders Market by Type
5.3. Drug Therapy
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Drug stores and retail pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online pharmacies
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: BLEEDING DISORDERS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Disease Type
7.2.3. Market size and forecast, by Treatment Type
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Disease Type
7.2.5.1.3. Market size and forecast, by Treatment Type
7.2.5.1.4. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Disease Type
7.2.5.2.3. Market size and forecast, by Treatment Type
7.2.5.2.4. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Disease Type
7.2.5.3.3. Market size and forecast, by Treatment Type
7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Disease Type
7.3.3. Market size and forecast, by Treatment Type
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Disease Type
7.3.5.1.3. Market size and forecast, by Treatment Type
7.3.5.1.4. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Disease Type
7.3.5.2.3. Market size and forecast, by Treatment Type
7.3.5.2.4. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Disease Type
7.3.5.3.3. Market size and forecast, by Treatment Type
7.3.5.3.4. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Disease Type
7.3.5.4.3. Market size and forecast, by Treatment Type
7.3.5.4.4. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Disease Type
7.3.5.5.3. Market size and forecast, by Treatment Type
7.3.5.5.4. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Disease Type
7.3.5.6.3. Market size and forecast, by Treatment Type
7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Disease Type
7.4.3. Market size and forecast, by Treatment Type
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Disease Type
7.4.5.1.3. Market size and forecast, by Treatment Type
7.4.5.1.4. Market size and forecast, by Distribution Channel
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Disease Type
7.4.5.2.3. Market size and forecast, by Treatment Type
7.4.5.2.4. Market size and forecast, by Distribution Channel
7.4.5.3. Australia
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Disease Type
7.4.5.3.3. Market size and forecast, by Treatment Type
7.4.5.3.4. Market size and forecast, by Distribution Channel
7.4.5.4. India
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Disease Type
7.4.5.4.3. Market size and forecast, by Treatment Type
7.4.5.4.4. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Disease Type
7.4.5.5.3. Market size and forecast, by Treatment Type
7.4.5.5.4. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Disease Type
7.4.5.6.3. Market size and forecast, by Treatment Type
7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Disease Type
7.5.3. Market size and forecast, by Treatment Type
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Disease Type
7.5.5.1.3. Market size and forecast, by Treatment Type
7.5.5.1.4. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Disease Type
7.5.5.2.3. Market size and forecast, by Treatment Type
7.5.5.2.4. Market size and forecast, by Distribution Channel
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Disease Type
7.5.5.3.3. Market size and forecast, by Treatment Type
7.5.5.3.4. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Disease Type
7.5.5.4.3. Market size and forecast, by Treatment Type
7.5.5.4.4. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Pfizer Inc.
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Novo Nordisk A/S
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. Bayer AG
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. Octapharma AG
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Sanofi
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Medexus Pharma, Inc.
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. Grifols, S.A.
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. F. Hoffmann-La Roche Ltd.
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. CSL Limited
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. Takeda Pharmaceutical Company Limited
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
9.10.7. Key strategic moves and developments
LIST OF TABLES
TABLE 01. GLOBAL BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 02. BLEEDING DISORDERS MARKET FOR HEMOPHILIA A, BY REGION, 2022-2032 ($MILLION)
TABLE 03. BLEEDING DISORDERS MARKET FOR HEMOPHILIA B, BY REGION, 2022-2032 ($MILLION)
TABLE 04. BLEEDING DISORDERS MARKET FOR VON WILLEBRAND DISEASE, BY REGION, 2022-2032 ($MILLION)
TABLE 05. BLEEDING DISORDERS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 06. GLOBAL BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 07. BLEEDING DISORDERS MARKET FOR FACTOR REPLACEMENT THERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 08. GLOBAL FACTOR REPLACEMENT THERAPY BLEEDING DISORDERS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 09. BLEEDING DISORDERS MARKET FOR DRUG THERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 10. GLOBAL BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 11. BLEEDING DISORDERS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 12. BLEEDING DISORDERS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 13. BLEEDING DISORDERS MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 14. BLEEDING DISORDERS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 18. NORTH AMERICA BLEEDING DISORDERS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 19. U.S. BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 20. U.S. BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 21. U.S. BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 22. CANADA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 23. CANADA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 24. CANADA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 25. MEXICO BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 26. MEXICO BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 27. MEXICO BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 28. EUROPE BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 29. EUROPE BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 30. EUROPE BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 31. EUROPE BLEEDING DISORDERS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 32. GERMANY BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 33. GERMANY BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 34. GERMANY BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 35. FRANCE BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 36. FRANCE BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 37. FRANCE BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 38. UK BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 39. UK BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 40. UK BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 41. ITALY BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 42. ITALY BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 43. ITALY BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 44. SPAIN BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 45. SPAIN BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 46. SPAIN BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 47. REST OF EUROPE BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 48. REST OF EUROPE BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 49. REST OF EUROPE BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 50. ASIA-PACIFIC BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 52. ASIA-PACIFIC BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 53. ASIA-PACIFIC BLEEDING DISORDERS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 54. JAPAN BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 55. JAPAN BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 56. JAPAN BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 57. CHINA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 58. CHINA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 59. CHINA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 60. AUSTRALIA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 61. AUSTRALIA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 62. AUSTRALIA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 63. INDIA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 64. INDIA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 65. INDIA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 66. SOUTH KOREA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 67. SOUTH KOREA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 68. SOUTH KOREA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 71. REST OF ASIA-PACIFIC BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 72. LAMEA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 73. LAMEA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 74. LAMEA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 75. LAMEA BLEEDING DISORDERS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 76. BRAZIL BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 77. BRAZIL BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 78. BRAZIL BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 79. SAUDI ARABIA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 80. SAUDI ARABIA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 81. SAUDI ARABIA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 82. SOUTH AFRICA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 83. SOUTH AFRICA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 84. SOUTH AFRICA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 85. REST OF LAMEA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 86. REST OF LAMEA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 87. REST OF LAMEA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 88. PFIZER INC.: KEY EXECUTIVES
TABLE 89. PFIZER INC.: COMPANY SNAPSHOT
TABLE 90. PFIZER INC.: PRODUCT SEGMENTS
TABLE 91. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 92. PFIZER INC.: KEY STRATERGIES
TABLE 93. NOVO NORDISK A/S: KEY EXECUTIVES
TABLE 94. NOVO NORDISK A/S: COMPANY SNAPSHOT
TABLE 95. NOVO NORDISK A/S: PRODUCT SEGMENTS
TABLE 96. NOVO NORDISK A/S: PRODUCT PORTFOLIO
TABLE 97. NOVO NORDISK A/S: KEY STRATERGIES
TABLE 98. BAYER AG: KEY EXECUTIVES
TABLE 99. BAYER AG: COMPANY SNAPSHOT
TABLE 100. BAYER AG: PRODUCT SEGMENTS
TABLE 101. BAYER AG: PRODUCT PORTFOLIO
TABLE 102. OCTAPHARMA AG: KEY EXECUTIVES
TABLE 103. OCTAPHARMA AG: COMPANY SNAPSHOT
TABLE 104. OCTAPHARMA AG: PRODUCT SEGMENTS
TABLE 105. OCTAPHARMA AG: PRODUCT PORTFOLIO
TABLE 106. OCTAPHARMA AG: KEY STRATERGIES
TABLE 107. SANOFI: KEY EXECUTIVES
TABLE 108. SANOFI: COMPANY SNAPSHOT
TABLE 109. SANOFI: PRODUCT SEGMENTS
TABLE 110. SANOFI: PRODUCT PORTFOLIO
TABLE 111. SANOFI: KEY STRATERGIES
TABLE 112. MEDEXUS PHARMA, INC.: KEY EXECUTIVES
TABLE 113. MEDEXUS PHARMA, INC.: COMPANY SNAPSHOT
TABLE 114. MEDEXUS PHARMA, INC.: PRODUCT SEGMENTS
TABLE 115. MEDEXUS PHARMA, INC.: PRODUCT PORTFOLIO
TABLE 116. MEDEXUS PHARMA, INC.: KEY STRATERGIES
TABLE 117. GRIFOLS, S.A.: KEY EXECUTIVES
TABLE 118. GRIFOLS, S.A.: COMPANY SNAPSHOT
TABLE 119. GRIFOLS, S.A.: PRODUCT SEGMENTS
TABLE 120. GRIFOLS, S.A.: PRODUCT PORTFOLIO
TABLE 121. GRIFOLS, S.A.: KEY STRATERGIES
TABLE 122. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 123. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 124. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 125. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 126. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
TABLE 127. CSL LIMITED: KEY EXECUTIVES
TABLE 128. CSL LIMITED: COMPANY SNAPSHOT
TABLE 129. CSL LIMITED: PRODUCT SEGMENTS
TABLE 130. CSL LIMITED: PRODUCT PORTFOLIO
TABLE 131. CSL LIMITED: KEY STRATERGIES
TABLE 132. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY EXECUTIVES
TABLE 133. TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT
TABLE 134. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT SEGMENTS
TABLE 135. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO
TABLE 136. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY STRATERGIES
LIST OF FIGURES
FIGURE 01. BLEEDING DISORDERS MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF BLEEDING DISORDERS MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN BLEEDING DISORDERS MARKET (2023-2032)
FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 05. LOW BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. LOW THREAT OF NEW ENTRANTS
FIGURE 08. LOW INTENSITY OF RIVALRY
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALBLEEDING DISORDERS MARKET
FIGURE 10. BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022(%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF BLEEDING DISORDERS MARKET FOR HEMOPHILIA A, BY COUNTRY 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF BLEEDING DISORDERS MARKET FOR HEMOPHILIA B, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF BLEEDING DISORDERS MARKET FOR VON WILLEBRAND DISEASE, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF BLEEDING DISORDERS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF BLEEDING DISORDERS MARKET FOR FACTOR REPLACEMENT THERAPY, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF BLEEDING DISORDERS MARKET FOR DRUG THERAPY, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF BLEEDING DISORDERS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF BLEEDING DISORDERS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF BLEEDING DISORDERS MARKET FOR ONLINE PHARMACIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 22. BLEEDING DISORDERS MARKET BY REGION, 2022
FIGURE 23. U.S. BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
FIGURE 24. CANADA BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
FIGURE 25. MEXICO BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
FIGURE 26. GERMANY BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
FIGURE 27. FRANCE BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
FIGURE 28. UK BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
FIGURE 29. ITALY BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
FIGURE 30. SPAIN BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
FIGURE 31. REST OF EUROPE BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
FIGURE 32. JAPAN BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
FIGURE 33. CHINA BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
FIGURE 34. AUSTRALIA BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
FIGURE 35. INDIA BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
FIGURE 36. SOUTH KOREA BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
FIGURE 37. REST OF ASIA-PACIFIC BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
FIGURE 38. BRAZIL BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
FIGURE 39. SAUDI ARABIA BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
FIGURE 40. SOUTH AFRICA BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
FIGURE 41. REST OF LAMEA BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 46. COMPETITIVE DASHBOARD
FIGURE 47. COMPETITIVE HEATMAP: BLEEDING DISORDERS MARKET
FIGURE 48. TOP PLAYER POSITIONING, 2022
FIGURE 49. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 50. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 51. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 52. NOVO NORDISK A/S: NET SALES, 2020-2022 ($MILLION)
FIGURE 53. NOVO NORDISK A/S: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 54. NOVO NORDISK A/S: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 55. BAYER AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 56. BAYER AG: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)
FIGURE 57. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 58. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 59. OCTAPHARMA AG: SALES REVENUE, 2020-2022 ($MILLION)
FIGURE 60. SANOFI S.A.: NET SALES, 2020-2022 ($MILLION)
FIGURE 61. SANOFI S.A.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 62. SANOFI S.A.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 63. MEDEXUS PHARMA, INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 64. MEDEXUS PHARMA, INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 65. GRIFOLS, S.A.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 66. GRIFOLS, S.A.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 67. GRIFOLS, S.A.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 68. F. HOFFMANN-LA ROCHE LTD.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 69. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 70. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 71. CSL LIMITED: SALES REVENUE, 2020-2022 ($MILLION)
FIGURE 72. CSL LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 73. CSL LIMITED: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 74. TAKEDA PHARMACEUTICAL COMPANY LIMITED: NET REVENUE, 2019-2021 ($MILLION)

$5,730
$3,840
$6,450
$9,600

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings